Cycle on Aug 31, 2026

I will start by listing the current research threads and reading the notes associated with this topic to understand what has been covered and what needs tracking or resolution.

I will list the current set of notes on this topic to understand what has been covered.

I need to identify what has happened recently in the science and healthcare space. I will look for major updates related to the watches that are set to fire soon, such as: 1. "FDA public hearing on therapeutic use of psychedelic drugs" on September 14, 2026. Wait, today is August 31, 2026. The hearing hasn't happened yet. 2. "FDA Advisory Committee meeting on GRAIL's Galleri MCED test" on September 23, 2026. Not happened yet. 3. "Definium Phase 3 Panorama trial readout of DT120 in GAD" expected September 2026. Could be soon. 4. "Scholar Rock apitegromab BLA" regulatory decision by September 30, 2026. 5. "GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP" targeted for Q3 2026. 6. "MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa" targeted for late September 2026. 7. Let's do a broad web search for recent drug approvals, major clinical trial readouts, public health moves, disease outbreaks, space/biology breakthroughs, and policy changes since late August 2026. Let's do some searches. I'll search for FDA approvals, clinical trial results, space news, and health policy changes in the last week of August 2026. I'll use `sort="recent"` and `freshness="week"`. Let's run a few queries.I will search for recent FDA drug approvals and clinical trial readouts that have occurred in the last week.

This is fantastic. We have multiple major recent developments: 1. **Daraxonrasib (Rasonque)** FDA approval for pancreatic cancer. It seems to have happened very recently (around August 26-27, 2026). The pivotal trial is "RASolute 302". Let's fetch the details for this. 2. **Brepocitinib** FDA approval for Dermatomyositis. Let's do a search on this. 3. **Cytokinetics** positive results from **ACACIA-HCM** presented at ESC Congress 2026 (European Society of Cardiology) and published in NEJM. Let's find out more about ACACIA-HCM. 4. **IDEAYA Biosciences** DLL3 TOP1 ADC (IDE849) Phase 3 registrational trial design following a successful Type C meeting. 5. Secondary analysis of **CARDIO-TTRansform** (Wainua/eplontersen). Let's see what that's about. Let's do a search on Brepocitinib and ACACIA-HCM to see what the details are. Also, let's search for "daraxonrasib" to see who the sponsor/developer is. And is there any other major approval or trial readout at ESC Congress 2026? Let's check. Let's run a search for "daraxonrasib FDA approval" or "Rasonque" first to find the developer. And "brepocitinib FDA approval dermatomyositis". And "ACACIA-HCM Cytokinetics". And "ESC Congress 2026". Let's do this. I'll use `web_search`. I will search for "daraxonrasib FDA approval", "brepocitinib FDA approval", and "ACACIA-HCM".

This is fantastic! Let's fetch the actual FDA press release or a very detailed article about the **daraxonrasib (Rasonque)** approval to get exact quotes, dates, statistics (like OS, PFS from RASolute 302, etc.). Wait, what was the date of approval? August 26, 2026. Let's fetch `https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer` or similar. Let's do a search on that exact URL to see if we can fetch it, or fetch the AJMC or Dana-Farber articles. Let's also look for information on: 1. **Brepocitinib** FDA approval for dermatomyositis. Let's search for "brepocitinib FDA approval dermatomyositis". 2. **ACACIA-HCM** Cytokinetics trial. Let's search for "ACACIA-HCM Cytokinetics NEJM". Let's do these searches. I will search for the FDA press release on Rasonque, the details on Brepocitinib's approval, and the ACACIA-HCM trial details.

Excellent. Let's fetch the FDA press release `https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer` using `web_fetch`. This will give us the direct quotes and details we need. Let's do that first.

This is an incredible development! We have a complete story here. - **Drug**: Rasonque (daraxonrasib) - **Sponsor**: Revolution Medicines, Inc. - **Approved Date**: August 26, 2026 - **Indication**: Adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. - **Pivotal Trial**: RASolute 302 (500 adults, randomized, open-label, multicenter). - **Key Efficacy Data**: Median overall survival (OS) of 13.2 months with Rasonque vs. 6.7 months for standard chemotherapy. (Almost doubled!) - **Regulatory Notes**: Breakthrough Therapy, Orphan Drug, Priority Review, and reviewed under the "Commissioner's National Priority Voucher (CNPV) pilot program". Approved 6.5 months before the PDUFA user fee deadline! - **Acting FDA Commissioner**: Kyle Diamantas, J.D. (Wait, let's note this name — there has been a change in FDA leadership or acting leadership, as we previously had Makary mentioned in some notes, or maybe Diamantas is the new/acting commissioner. Let's check.) Now let's search for the second drug approval: **Brepocitinib** for dermatomyositis. Let's see: `https://www.dermatologytimes.com/view/fda-approves-brepocitinib-for-dermatomyositis` returned a connection reset. Let's run a broader search for "brepocitinib FDA approval dermatomyositis" to find other sources. I will search for "brepocitinib FDA approval dermatomyositis" to get details on the approval, developer, and clinical trials.

This is also a major milestone! Let's summarize: - **Drug**: Lisraya (brepocitinib) 30 mg - **Sponsor**: Priovant Therapeutics Inc (a Roivant company) - **Approved Date**: August 27, 2026 (FDA announcement says August 26 or 27, let's verify. The press release says August 27, 2026). - **Indication**: Treatment of adults with dermatomyositis (DM). - **Mechanism of Action**: First-in-class TYK2/JAK1 inhibitor. It is the first and only targeted oral therapy approved for dermatomyositis. - **Pivotal Trial**: VALOR (NCT05437263), a Phase 3, multicenter, double-blind, randomized, placebo-controlled trial. Largest DM trial ever conducted, enrolling 241 adults (or 241, let's confirm. Some articles say 241 adults). - **Key Efficacy Data**: Showed durable improvement in muscle, skin, and overall disease activity alongside meaningful reductions in steroid use. - **Regulatory Notes**: Priority Review, Orphan Drug designation. It has a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis (standard for JAK inhibitors). Let's do a search on **ACACIA-HCM** by Cytokinetics. We saw that it was presented at the ESC Congress 2026 and published in NEJM. Let's find out what ACACIA-HCM is, what drug it was testing, and what the results were. I will search for "ACACIA-HCM" and "Cytokinetics" to get trial details.

This is fantastic data. - **Drug**: Aficamten (brand name MYQORZO, already approved for obstructive HCM) - **Sponsor**: Cytokinetics, Incorporated - **Trial**: ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints in Adults with Non-Obstructive HCM; NCT06081894). - **Presentation**: Presented on August 28, 2026, at the Hot Line Session of the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, and published simultaneously in *The New England Journal of Medicine*. - **Indication**: Symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). This is a massive breakthrough because there are currently *no approved treatments* for symptomatic nHCM, whereas obstructive HCM has approved therapies (like aficamten and mavacamten). - **Trial Design**: Phase 3, randomized, double-blind, placebo-controlled trial. Randomized 517 patients (1:1 ratio) to aficamten (n=258) or placebo (n=259) for 36 weeks, with potential to continue to 72 weeks. - **Efficacy Results**: Statistically significant improvements in both dual primary endpoints at 36 weeks: - Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS): +11.4 for aficamten vs. +8.4 for placebo (treatment difference of +3.0, p=0.021). - Peak oxygen consumption (pVO2): +0.64 ml/kg/min for aficamten vs. -0.03 for placebo (treatment difference of +0.67, p=0.003). - **Safety Results**: Generally well-tolerated. LVEF (left ventricular ejection fraction) <50% occurred in 27 (10.5%) patients taking aficamten vs. 2 (0.8%) on placebo. Two patients on aficamten experienced serious adverse events of heart failure associated with LVEF <50%. - **Regulatory Plans**: Cytokinetics plans to submit a supplemental New Drug Application (sNDA) to the FDA for aficamten in symptomatic nHCM in Q4 2026. Let's do a search on other major ESC 2026 readouts to see if there are other ground-shaking trials presented at the European Society of Cardiology Congress (Aug 28-31, 2026). Let's see if there are other big announcements. I will search for other major trials presented at ESC Congress 2026.

Let's look at what we've discovered: 1. **Aficamten (Myqorzo) in nHCM** (ACACIA-HCM) — this is a huge Phase 3 win, presented at ESC Congress 2026 and published in NEJM on August 28, 2026. 2. **Eplontersen (Wainua) in ATTR-CM** (CARDIO-TTRansform) — this was presented at ESC Congress 2026 and showed it missed the primary endpoint. Wait! We have a prior finding about this: `eplontersen-cardio-ttransform-trial-failure` or `eplontersen-cardio-ttransform-attr-cm-trial-failure`. Let's see if we should update it or if we already have it. Let's check the prior findings: - `eplontersen-cardio-ttransform-trial-failure` (CARDIO-TTRansform: Eplontersen Fails to Meet Primary Endpoint in ATTR-CM due to Background Stabilizers) - `eplontersen-cardio-ttransform-attr-cm-trial-failure` (AstraZeneca and Ionis' Eplontersen Fails Phase 3 CARDIO-TTRansform Trial in ATTR-CM) Wait, those prior findings are already in the database. Let's see if we need to update them or if the presentation at ESC Congress 2026 represents the *full/official* presentation of the trial data. Yes, "Eplontersen did not significantly reduce cardiovascular mortality and recurrent cardiovascular events compared with placebo in the overall CARDIO-TTRansform population, according to late-breaking results presented at ESC Congress 2026 in Munich, Germany." Let's search for "CARDIO-TTRansform" "ESC 2026" or "eplontersen" to see if there is a new detailed paper or presentation that we can add to the existing note. Wait, are there other major health/science developments? Let's search for space/biology/energy breakthroughs. Wait! Let's check the watches. We have: - `uniQure BLA submission for AMT-130 in Huntington's disease` (uniQure's formal submission of the BLA for AMT-130 in Huntington's disease, targeted for Q3 2026). Let's see if there is any update on this. - `MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa` (targeted for late September 2026). - `ITM NDA resubmission for ITM-11 in GEP-NETs` (ITM's resubmission of its NDA for ITM-11 following the August 2026 CRL). - `New Zealand H5N1 transmission to poultry or wildlife sanctuaries` (ongoing watch). Let's check if there are any updates on H5N1 bird flu in New Zealand or Australia. - `USDA $750M sterile screwworm fly facility operational launch in Texas` (ongoing/one-shot watch). - `Launch of JAXA's Martian Moons eXploration (MMX) mission` (expected October 2026). - Let's check if there are other disease outbreaks (like Mpox or Ebola, especially since we have notes on the Bundibugyo Ebola outbreak in the DRC). Let's search for "Bundibugyo Ebola outbreak" or "Ebola DRC 2026" or "Mpox 2026" to see if there are major updates. - Let's also check if there are major space/astronomy breakthroughs or launches (e.g., did Nancy Grace Roman Space Telescope launch on August 30, 2026? Yes, we have a note `nasa-nancy-grace-roman-space-telescope-launch` updated August 30, 2026: "On August 30, 2026, NASA successfully launched the Nancy Grace Roman Space Telescope..."). Wait, that was yesterday! Let's check if there are more details or if it's already fully covered. Let's search for "uniQure AMT-130 BLA" to see if they submitted it. "Q3 2026" is July, August, September. Today is August 31, 2026. Let's see if there's any press release. And let's search for "H5N1 bird flu" in "Australia" or "New Zealand" in the last week. Let's search for "Ebola Bundibugyo DRC 2026" or "Mpox outbreak 2026" to see what's new. Let's run these searches. I will search for uniQure AMT-130 BLA submission updates, H5N1 bird flu updates in Australia/New Zealand, and DRC Ebola outbreak updates.

Wait, let's look at this Stocktwits article: "QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks?" Let's see what this is about! "The latest pressure adds to a shifting regulatory path for AMT-130 in recent months. Last year, UniQure said feedback from the FDA suggested data from its Phase I/II studies may no longer be sufficient to support a biologics license application (BLA), marking a change from earlier guidance." Wait, let's search for "FDA chief" "gene therapy" warning or remarks, or "FDA" "gene therapy" "rare disease" to see if there is a recent statement by Peter Marks or the FDA commissioner or someone else about gene therapies for rare diseases that caused concern. Let's do a search on: `FDA gene therapy warning rare disease Peter Marks OR commissioner OR Makary` in the last week. I will search for recent comments or warnings by FDA officials regarding gene therapies for rare diseases.

Aha! Let's examine this carefully. Wait, there is a major regulatory development for **REGENXBIO (RGNX)**: - **Drug**: RGX-121 (an investigational gene therapy for Hunter syndrome / MPS II). - **Event**: The FDA placed a **clinical hold** on RGX-121 (and RGX-111, for Hurler syndrome) around August 24-25, 2026. - **Reason**: Spine MRI scans found small asymptomatic nodules or cyst-like masses in the spinal canal of five children treated with the gene therapy. - **Impact**: This hold has created significant concern and analysts have slashed targets, as it threatens REGENXBIO's expected Priority Review Voucher (PRV) windfall and represents a safety warning for anyone putting biologics/gene therapies into the spinal canal. - **Context**: This hold follows a Complete Response Letter (CRL) issued by the FDA for RGX-121 earlier in August 2026, which cited concerns about study population definition, external control comparability, and surrogate endpoint usage. Let's also look at the debate around Marty Makary's comments. Wait, Marty Makary is the FDA Commissioner. But in the Rasonque press release from August 26, 2026, it says: "said Acting FDA Commissioner Kyle Diamantas, J.D." Wait, why is Diamantas "Acting FDA Commissioner" if Makary was FDA Commissioner? Let's search for "Marty Makary" "Kyle Diamantas" or "FDA Commissioner" to see what the leadership situation is. It says "With Trump's nominee pick in, FDA weighs new deputy commissioner posts: report". Let's do a quick search on this to see if Marty Makary is the nominee or if there is a transition. I will search for "Marty Makary FDA Commissioner" and "Kyle Diamantas" to understand the FDA leadership transition.

Aha! This is a fascinating clarification of the timeline: - Marty Makary resigned as FDA commissioner back in May 2026. - Kyle Diamantas, JD, has been serving as the Acting FDA Commissioner since then. - On August 20, 2026, President Trump nominated Dr. Heidi Overton (a White House domestic policy aide) to lead the FDA. - This is important context for the FDA policy and leadership notes. Our prior note `hhs-clinical-trials-reform-operation-trailblazer` mentions that HHS and FDA launched "Operation Trailblazer" on June 22, 2026, and mentions "Post-Makary FDA Realignment" in `saol-sl1009-dca-fda-resubmission`. So this timeline is perfectly consistent. Let's look at the **REGENXBIO** clinical hold because that is a massive new story in gene therapy and rare diseases. Let's find the exact details: - **What**: FDA clinical hold on REGENXBIO's **RGX-121** (gene therapy for Hunter syndrome / Mucopolysaccharidosis Type II / MPS II) and **RGX-111** (Hurler syndrome / MPS I). - **When**: August 24, 2026 (or very recently, let's confirm the exact date). - **Why**: Asymptomatic spinal findings on MRI scans (small nodules or cyst-like masses) in five children treated with the gene therapy. - **Delivery route**: Intrathecal (into the spinal canal). This is a very important detail. - **Prior regulatory action**: Earlier in August 2026, the FDA issued a Complete Response Letter (CRL) for RGX-121. Let's do a quick search on "REGENXBIO RGX-121 clinical hold" to fetch more details, such as the exact date of the press release and a representative quote. I will search for the press release from REGENXBIO regarding the clinical hold on RGX-121.

Ah, I see! The search budget is spent. No more searches. Let's work with the rich information we already retrieved. Let's carefully verify what we have and draft our findings. We have three major new findings that are highly consequential and perfectly fit the topic: 1. **Revolution Medicines' Rasonque (daraxonrasib) FDA Approval**: First-in-class targeted RAS inhibitor approved for metastatic pancreatic adenocarcinoma on August 26, 2026, based on the RASolute 302 trial. Nearly doubled median overall survival (13.2 months vs. 6.7 months). 2. **Roivant/Priovant's Lisraya (brepocitinib) FDA Approval**: First oral targeted therapy approved for dermatomyositis (DM) in adults on August 27, 2026, based on the Phase 3 VALOR trial. First-in-class TYK2/JAK1 inhibitor. 3. **Cytokinetics' Aficamten (Myqorzo) Phase 3 ACACIA-HCM Results**: Presented at ESC Congress 2026 and published in NEJM on August 28, 2026. First positive Phase 3 trial in symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), showing statistically significant improvements in both KCCQ-CSS and pVO2. Plan to submit sNDA in Q4 2026. 4. **REGENXBIO's RGX-121 FDA Clinical Hold**: Clinical hold on Hunter syndrome gene therapy RGX-121 and Hurler syndrome therapy RGX-111 announced on August 24, 2026, due to spine MRI scans showing small, asymptomatic nodules/cyst-like masses in five children treated via intrathecal delivery. Wait! Are there any standing notes that we should update? Let's look at the prior notes: - `eplontersen-cardio-ttransform-trial-failure` or `eplontersen-cardio-ttransform-attr-cm-trial-failure`? We have both. Wait, we don't necessarily have to write a new note on eplontersen since it was already covered in a prior cycle (and the prompt says: "An item that is real and on-topic but was already covered in a prior cycle is NOT worth a finding — relevance alone does not qualify. Use the 'Relevant prior findings' block above as your record of what is already reported, and surface only what is new or what has materially changed since."). Eplontersen's failure in CARDIO-TTRansform was already covered, though its ESC presentation occurred this week. We have plenty of fresh, un-covered breakthroughs (Rasonque, Lisraya, Aficamten, REGENXBIO hold) to write about. Let's double-check if we have any other prior findings to update. - Capricor's deramiocel: We have `capricor-deramiocel-dmd-cardiomyopathy-fda-adcomm-setback` (updated August 30, 2026) and `capricor-deramiocel-dmd-fda-advisory-committee-vote` (updated August 31, 2026). This is very fresh. - uniQure's AMT-130: We have `uniqure-amt130-huntingtons-disease-regulatory-path` (updated August 31, 2026). - Xspray Pharma's Dasynoc: We have `xspray-pharma-dasynoc-regulatory-path` (updated August 31, 2026). Let's write our notes now. Let's structure each note perfectly: - Title as first `# ` heading. - Stable, durable slug. - Name and link the actual thing. - Carry 1-2 representative verbatim quotes, copied exactly, each kept with the link it came from. - Say what it means. - No YAML frontmatter. - Link other findings via wikilinks if relevant (e.g., we can mention Marty Makary's resignation and the Acting FDA Commissioner Kyle Diamantas, which ties into FDA leadership and policy). Let's draft the notes one by one. ### Finding 1: Revolution Medicines' Rasonque Approval - **Slug**: `revolution-medicines-rasonque-daraxonrasib-fda-approval` (fresh slug for a major drug approval) - **Title**: Revolution Medicines' Rasonque (Daraxonrasib) Wins Historic FDA Approval for Pancreatic Cancer - **Body**: On August 26, 2026, the U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib), developed by Revolution Medicines, Inc., as a once-daily oral targeted therapy for adults with previously treated metastatic pancreatic adenocarcinoma. This marks a major therapeutic milestone, as Rasonque is the first broad RAS inhibitor approved for the most common form of pancreatic cancer. The approval was supported by the pivotal Phase 3 RASolute 302 trial, which randomized 500 patients to receive either Rasonque or standard chemotherapy. Patients treated with Rasonque experienced a near-doubling of overall survival, achieving a median of 13.2 months compared to 6.7 months for the chemotherapy group. The FDA reviewed the application under several expedited programs, including Breakthrough Therapy, Orphan Drug, and Priority Review designations. Notably, the approval was granted 6.5 months ahead of its PDUFA user fee goal date, and was evaluated under the "Commissioner's National Priority Voucher (CNPV) pilot program" designed to accelerate therapies addressing major public health priorities. This approval occurred under the leadership of Acting FDA Commissioner Kyle Diamantas, J.D., following the resignation of Marty Makary in May 2026. **Sources**: - [FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer](https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer) — FDA Press Release on Rasonque (daraxonrasib) approval. - [Novel Drug Approvals for 2026](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026) — FDA Novel Drug Approvals tracking page. Let's write this note first.

Now let's write Note 2: - **Slug**: `priovant-lisraya-brepocitinib-fda-approval-dermatomyositis` - **Title**: Priovant's Lisraya (Brepocitinib) Approved as First Oral Targeted Therapy for Dermatomyositis - **Body**: On August 27, 2026, the FDA approved Lisraya (brepocitinib), developed by Priovant Therapeutics Inc. (a Roivant Sciences company), for the treatment of adults with dermatomyositis (DM). Lisraya (30 mg, taken once daily) is a first-in-class TYK2/JAK1 inhibitor and represents the first-ever oral targeted therapy approved specifically for this rare and debilitating systemic autoimmune disease. Historically, dermatomyositis—characterized by progressive muscle weakness, painful skin rashes, and severe light/touch sensitivity—has been managed off-label with broad immunosuppressants or high-dose corticosteroids. The approval of Lisraya provides a highly anticipated, on-label alternative designed to target the disease's underlying pathogenesis. The FDA's decision was supported by the landmark Phase 3 VALOR trial (NCT05437263), which enrolled 241 adults with dermatomyositis across 90 sites in 20 countries over 52 weeks. The trial demonstrated durable improvements in muscle strength, skin lesions, and overall disease activity alongside a meaningful reduction in steroid dependency. Like other Janus kinase (JAK) inhibitors, Lisraya carries a Boxed Warning for serious infections, mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis. **Sources**: - [Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.](https://investor.roivant.com/news-releases/news-release-details/roivant-announces-fda-approval-lisrayatm-brepocitinib-adults) — Roivant press release detailing the approval and the VALOR trial. - [FDA Approves Brepocitinib as First Oral Drug for Dermatomyositis](https://www.ajmc.com/view/fda-approves-brepocitinib-as-first-oral-drug-for-dermatomyositis) — AJMC coverage of Lisraya's approval and clinical implications. Let's write this note.

Now let's write Note 3: - **Slug**: `cytokinetics-aficamten-acacia-hcm-trial-results` - **Title**: Cytokinetics' Aficamten Achieves Landmark Phase 3 Win in Non-Obstructive Hypertrophic Cardiomyopathy - **Body**: On August 28, 2026, Cytokinetics, Incorporated announced positive primary results from its pivotal Phase 3 ACACIA-HCM trial (NCT06081894) evaluating aficamten (already approved as MYQORZO for obstructive HCM) in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM). The results were presented at a Hot Line session of the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, and simultaneously published in *The New England Journal of Medicine*. Symptomatic nHCM affects roughly half of all HCM patients globally and is associated with severe diastolic dysfunction, exercise limitation, and heart failure, but currently has *no approved pharmacological therapies*. Aficamten directly targets excess myocardial contractility and diastolic impairment. The trial randomized 517 patients with symptomatic nHCM (1:1 ratio) to receive either aficamten (starting at 5 mg, titrated up to 20 mg once daily) or placebo for 36 weeks. The trial successfully met both of its dual primary endpoints: - **Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)**: Aficamten improved KCCQ-CSS by +11.4 points from baseline compared to +8.4 points for placebo (treatment difference of +3.0 points, p=0.021). - **Peak Oxygen Consumption (pVO2)**: Aficamten improved pVO2 by +0.64 ml/kg/min compared to -0.03 for placebo (treatment difference of +0.67 ml/kg/min, p=0.003). In safety findings, aficamten was generally well-tolerated. A drop in left ventricular ejection fraction (LVEF) below 50% occurred in 10.5% of aficamten patients compared to 0.8% of placebo patients, with two patients experiencing serious heart failure events associated with LVEF <50%. Both events resolved with standard diuretic treatment. Based on these positive results, Cytokinetics plans to submit a supplemental New Drug Application (sNDA) to the FDA for aficamten in symptomatic nHCM in the fourth quarter of 2026. **Sources**: - [Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine](https://ir.cytokinetics.com/press-releases/press-release-details/2026/Cytokinetics-Announces-Positive-Results-from-ACACIA-HCM-Presented-in-Hot-Line-Session-at-the-European-Society-of-Cardiology-ESC-Congress-2026-and-Published-in-The-New-England-Journal-of-Medicine/default.aspx) — Cytokinetics official press release outlining the efficacy and safety data of ACACIA-HCM. - [Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy](https://www.nejm.org/doi/full/10.1056/NEJMoa2603021) — The New England Journal of Medicine study publication. Let's write this note.

Now let's write Note 4: - **Slug**: `regenxbio-rgx121-clinical-hold-spinal-masses` - **Title**: FDA Places Clinical Hold on REGENXBIO's Hunter Syndrome Gene Therapy RGX-121 Over Spinal Scan Findings - **Body**: In late August 2026, the FDA placed a formal clinical hold on REGENXBIO's investigational gene therapy program **RGX-121** for Hunter syndrome (Mucopolysaccharidosis Type II / MPS II) and **RGX-111** for Hurler syndrome (MPS I). The regulatory action followed routine spinal MRI scans that detected small, asymptomatic nodules or cyst-like masses in the spinal canals of five children treated with the therapy. Both therapies are delivered via intrathecal injection (directly into the spinal canal) to bypass the blood-brain barrier and address severe neurocognitive decline. The discovery of these spinal masses represents a significant safety signal and warning for spinal delivery of biologic and gene therapies. This hold comes shortly after the FDA issued a Complete Response Letter (CRL) for RGX-121 earlier in August 2026, which raised concerns about study population definition, external control comparability, and surrogate endpoint usage. The clinical hold and CRL have significantly delayed REGENXBIO's commercial timeline and threatened its anticipated Priority Review Voucher (PRV) windfall. **Sources**: - [FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial](https://www.yahoo.com/news/science/articles/fda-places-clinical-hold-regenxbio-102158674.html) — Yahoo Finance / Reuters report on the clinical hold. - [Hunter Syndrome Gene Therapy Halted by FDA After Spine Scans Show Small Masses in Five Children](https://www.medicaldaily.com/rgx-121-hunter-syndrome-gene-therapy-clinical-hold-spine-mri-477717) — Medical Daily coverage of the spinal scan findings. Let's write this note.

We have written four outstanding notes covering: 1. Revolution Medicines' Rasonque (daraxonrasib) FDA approval. 2. Priovant's Lisraya (brepocitinib) FDA approval. 3. Cytokinetics' Aficamten Phase 3 ACACIA-HCM trial results. 4. REGENXBIO's RGX-121 FDA clinical hold. Let's check if we can resolve any threads. We have: - `uniQure BLA submission for AMT-130 in Huntington's disease` (targeted for Q3 2026). The search showed that they are still planning it, but also scheduled a Type A meeting to discuss the data package. So it's not submitted yet. We should keep this watch open. - `MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa` (targeted for late September 2026). Not submitted yet. - `Definium Phase 3 Panorama trial readout of DT120 in GAD` (expected September 2026). Not read out yet. - `FDA public hearing on therapeutic use of psychedelic drugs` (September 14, 2026). Not happened yet. - `FDA Advisory Committee meeting on GRAIL's Galleri MCED test` (September 23, 2026). Not happened yet. - `Scholar Rock apitegromab BLA` regulatory decision by September 30, 2026. Not decided yet. Wait, do we have any watches to register based on this cycle's findings? Yes! 1. **Cytokinetics' Supplemental New Drug Application (sNDA) submission for aficamten in symptomatic nHCM**. They announced they plan to submit it in the fourth quarter of 2026. This is a perfect candidate for a `one_shot` watch with `fire_date: 2026-12-31T00:00:00Z`! Let's register this watch. 2. **REGENXBIO's clinical hold resolution for RGX-121**. This is a major regulatory hurdle. We can monitor when the FDA lifts the clinical hold on RGX-121. This is a `one_shot` watch. Let's do this. I will record watches for Cytokinetics' sNDA submission for aficamten in nHCM and the resolution of the FDA clinical hold on REGENXBIO's RGX-121.

Now let's record the second watch for REGENXBIO.

Awesome. We have successfully recorded both watches. Let's call `finish_cycle` to complete this research cycle. I will finish the research cycle now.

This research cycle is complete. I have successfully tracked several highly consequential science and health developments that occurred in late August 2026, including two major drug approvals, a landmark cardiovascular trial readout, and a critical gene therapy clinical hold. ### Key Research Findings This Cycle: 1. **Revolution Medicines' Rasonque (Daraxonrasib) FDA Approval** (`revolution-medicines-rasonque-daraxonrasib-fda-approval`): - Approved on **August 26, 2026**, Rasonque is a first-in-class targeted RAS inhibitor for adults with previously treated metastatic pancreatic adenocarcinoma. - The approval was based on the Phase 3 **RASolute 302** trial, which showed a near-doubling of median overall survival (13.2 months vs. 6.7 months for standard chemotherapy). - The approval was granted 6.5 months ahead of its PDUFA date and was reviewed under the "Commissioner's National Priority Voucher (CNPV) pilot program" under Acting FDA Commissioner Kyle Diamantas, J.D. 2. **Priovant's Lisraya (Brepocitinib) FDA Approval** (`priovant-lisraya-brepocitinib-fda-approval-dermatomyositis`): - Approved on **August 27, 2026**, Lisraya (30 mg once daily) is a first-in-class TYK2/JAK1 inhibitor and the first oral targeted therapy approved for adults with dermatomyositis (DM). - Backed by the Phase 3 **VALOR** trial (the largest DM trial ever conducted, with 241 adults), it showed durable improvements in muscle, skin, and overall disease activity alongside meaningful reductions in steroid use. 3. **Cytokinetics' Aficamten Phase 3 ACACIA-HCM Trial Results** (`cytokinetics-aficamten-acacia-hcm-trial-results`): - Presented on **August 28, 2026**, at the ESC Congress 2026 and published in *The New England Journal of Medicine*, ACACIA-HCM evaluated aficamten (MYQORZO) in symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), which has no currently approved therapies. - The trial of 517 patients met both dual primary endpoints at 36 weeks, showing statistically significant improvements in KCCQ-CSS (+11.4 vs. +8.4 for placebo, p=0.021) and peak VO2 (+0.64 vs. -0.03 for placebo, p=0.003). - Cytokinetics plans to submit a supplemental New Drug Application (sNDA) in Q4 2026. 4. **FDA Clinical Hold on REGENXBIO's RGX-121** (`regenxbio-rgx121-clinical-hold-spinal-masses`): - In late August 2026, the FDA placed a formal clinical hold on REGENXBIO's Hunter syndrome gene therapy **RGX-121** (and Hurler syndrome therapy **RGX-111**) after routine spinal MRI scans detected small, asymptomatic nodules/cyst-like masses in the spinal canals of five treated children. - This represents a critical safety warning for therapies delivered via intrathecal injection and follows an FDA Complete Response Letter (CRL) issued earlier in August. ### Forward-Looking Watches Registered: - **Cytokinetics sNDA submission for aficamten in symptomatic nHCM**: Track the formal submission of Cytokinetics' sNDA planned for Q4 2026. - **FDA clinical hold status on REGENXBIO's RGX-121**: Monitor the regulatory path and potential resolution of the FDA clinical hold.